PainReform (PRFX) Stock Price, News & Analysis

Company Overview

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Key Stats

• Today's Range: $2.23 to $2.32
• 50-Day Range: $1.75 to $3.71
• 52-Week Range: $1.68 to $23.27
• Volume: 37,610 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $2.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

PainReform Stock Analysis - MarketRank™

PainReform scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

PainReform has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

PainReform has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PainReform is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PainReform is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PainReform has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.34% of the float of PainReform has been sold short.

Short Interest Ratio / Days to Cover

PainReform has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PainReform has recently decreased by 37.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PainReform does not currently pay a dividend.

Dividend Growth

PainReform does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.34% of the float of PainReform has been sold short.

Short Interest Ratio / Days to Cover

PainReform has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PainReform has recently decreased by 37.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added PainReform to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PainReform insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 37.28% of the stock of PainReform is held by institutions.

PRFX Stock Analysis - Frequently Asked Questions

How have PRFX shares performed this year?

PainReform's stock was trading at $3.36 at the beginning of the year. Since then, PRFX shares have decreased by 31.0% and is now trading at $2.32.
View the best growth stocks for 2025 here.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($7.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($17.20) by $10.00.

When did PainReform's stock split?

Shares of PainReform reverse split on Thursday, November 21st 2024. The 1-4 reverse split was announced on Monday, November 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

When did PainReform IPO?

PainReform (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

How do I buy shares of PainReform?

Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PainReform investors own include Predictive Oncology (POAI), Bank of America (BAC), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Abbott Laboratories (ABT) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 4/24/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRFX
• CIK: 1801834
• Web: www.painreform.com
• Phone: 972-3717-7051
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +244.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($147.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,340,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -450.64%
• Return on Assets: -241.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $111.46 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 875,000
• Free Float: 95,000
• Market Cap: $2.03 million
• Optionable: Not Optionable
• Beta: 0.72